News | January 22, 2014

BeneChill Receives Frost & Sullivan Award for Intranasal Cooling System for Therapeutic Hypothermia

BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
January 22, 2014 — BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill intranasal cooling system. 
 
BeneChill's RhinoChill is a nasopharyngeal device that can induce and sustain therapeutic hypothermia during active resuscitation after cardiac arrest. The system is noninvasive, time critical and can be used by nonmedical personnel to prevent brain damage associated with cardiac arrest.
 
RhinoChill is portable and battery-operated with a control unit, coolant bottle and a transnasal cooling catheter to facilitate use outside of hospital settings. The technology enables brain cooling close to the time of cerebral ischemic events, including in the absence of blood circulation. RhinoChill's technology initially targets brain cooling and then body cooling during cardiac arrest and after resuscitation.
 
The technology maintains therapeutic hypothermia brain temperatures by deploying two 10 cm long nasal catheter prongs that spray a mist of liquid proprietary coolant into the nasal cavity. The sprayed coolant evaporates on contact with the internal nares of the skull and facilitates rapid heat transfer. Lungs expel the coolant as inert and nontoxic gas.
 
RhinoChill’s operating input voltage is 10 to 18 V DC, and the control unit draws little current to enable battery operation. Its dimensions are 39 x 26 x 16 cm and it weighs approximately 5 to 9 kg. The system's components can connect in 30 to 60 seconds and can deploy immediately. RhinoChill features an auto shut off that is responsive to pressure in the nasal cavity beyond a threshold.
 
BeneChill plans to expand the technology to other fields such as traumatic brain injury, neuroradiology, neurosurgery and cardiac surgery.
 
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry and the positive impact on brand perception.
 
For more information: www.benechill.com, www.frost.com

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
Overlay Init